FIELD: chemistry.
SUBSTANCE: group of inventions relates to organic chemistry and includes individual derivatives of 1,5-benzothiazepine presented below, pharmaceutically acceptable salts thereof, a pharmaceutical composition based on them and use thereof.
See table above.
EFFECT: technical result is 1,5-benzothiazepine derivatives possessing activity of inhibition of apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transporter (LBAT).
8 cl, 8 tbl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
BENZOTHIAZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2838460C1 |
BENZOTHIA(DI)AZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2021 |
|
RU2841263C1 |
BENZOTHIA(DI)AZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2827704C1 |
BENZOTHIADIAZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2838136C1 |
BENZOTHIAZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2817535C2 |
BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACIDS MODULATORS | 2020 |
|
RU2814570C2 |
BENZOTHIA(DI)AZEPINES AND THEIR USE AS BILE ACID MODULATORS | 2019 |
|
RU2785867C2 |
N1/N2-LACTAM ACETYL-CoA-CARBOXYLASE INHIBITORS | 2011 |
|
RU2540337C2 |
ANTIBODY-DRUG CONJUGATE CONTAINING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | 2021 |
|
RU2836814C1 |
PHARMACEUTICAL COMPOSITIONS CONTAINING PEPTIDE VERSIONS, AND METHODS OF USING THEM | 2015 |
|
RU2729161C2 |
Authors
Dates
2025-04-14—Published
2020-12-04—Filed